June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Characterization of real-world neovascular age-related macular degeneration (nAMD) switch patients treated with brolucizumab (BROL) alternating with other anti-Vascular Endothelial Growth Factors (VEGF) versus brolucizumab alone
Author Affiliations & Notes
  • Jasmyne McCoy
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Ryan Zubricky
    Northeastern Ohio Medical University, Rootstown, Ohio, United States
  • Samriddhi Buxy Sinha
    Novartis AG, Basel, Basel-Stadt, Switzerland
  • Nina Sonbolian
    Novartis AG, Basel, Basel-Stadt, Switzerland
  • Lujia Zhou
    KMK Consulting, Morristow, New Jersey, United States
  • Richard Donkor
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Christina McCrossin
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • David G Miller
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Hang Pham
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Jerome Schartman
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Llewelyn Rao
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Lawrence J Singerman
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Michael Novak
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Scott Pendergast
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Helene Karcher
    Novartis AG, Basel, Basel-Stadt, Switzerland
  • Joseph M Coney
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Footnotes
    Commercial Relationships   Jasmyne McCoy None; Ryan Zubricky None; Samriddhi Buxy Sinha None; Nina Sonbolian None; Lujia Zhou None; Richard Donkor None; Christina McCrossin None; David Miller Regeneron, Code C (Consultant/Contractor); Hang Pham None; Jerome Schartman None; Llewelyn Rao None; Lawrence Singerman None; Michael Novak None; Scott Pendergast None; Helene Karcher None; Joseph Coney Notal Vision, Genentech, Alimera, Regeneron, Allergan, , Code C (Consultant/Contractor), Aerpio, Novartis, Genentech, Allergan, Tyrogenex, Appelis, Alimera , Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1314 – F0148. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jasmyne McCoy, Ryan Zubricky, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou, Richard Donkor, Christina McCrossin, David G Miller, Hang Pham, Jerome Schartman, Llewelyn Rao, Lawrence J Singerman, Michael Novak, Scott Pendergast, Helene Karcher, Joseph M Coney; Characterization of real-world neovascular age-related macular degeneration (nAMD) switch patients treated with brolucizumab (BROL) alternating with other anti-Vascular Endothelial Growth Factors (VEGF) versus brolucizumab alone. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1314 – F0148.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To study real-world nAMD patients’ characteristics in two BROL regimens.

Methods : A retrospective cohort study at Retina Associates of Cleveland, Inc. (extracted on December 1, 2021) analyzed two nAMD groups, BROL alone and BROL alternating with other anti-VEGFs. BROL alone switched from a previous anti-VEGF, had at least 12 months follow-up post switch and at least 3 BROL injections and no other anti-VEGF in first 12 months of treatment post switch. BROL alternating switched from a previous anti-VEGF, had at least 12 months follow-up post switch and at least 3 BROL and 1 other anti-VEGF injection in first 12 months of treatment post switch. Injection intervals, visual acuity (VA), and central macular thickness (CMT) were analyzed at baseline (first BROL injection) and last follow-up, along with follow-up times distribution post first BROL injection. Inflammatory events were reported.

Results : BROL alone identified 172 eyes from 152 patients (53.3% females) with mean±standard deviation (SD) age, VA and CMT of 80.7±7.8 years, 1.14±0.87 logMAR and 300.7±118.1 μm respectively at baseline. BROL alternating identified 56 eyes from 49 patients (65.3% females) with similar baseline mean age, VA and CMT (77.5±9.0 years,1.04±0.75 logMAR and 299.3±91.0 μm respectively).

Alternating eyes had shorter pre-switch intervals (33.2±11.9 days) than BROL alone (48.8±25.8 days), and could extend interval by 8.4±20.5 days at last follow-up compared to 32.7±61.1 days for BROL alone (Table 1). Follow-up time (from first BROL injection) in BROL alternating and BROL alone was 564.3±107.0 days and 552.5 ±104.4 days, respectively. BROL alternating had no inflammatory events, 1.7% of BROL alone eyes did.

Mean change from first BROL injection to last follow-up in VA was a gain and CMT reduction in both groups (Table 1). BROL alone group saw largest CMT reduction (-39.6 μm) compared to alternating group (-28.5 μm) (Table 1), consistent with fluids volume reduction within retinal layers (Table 2).

Conclusions : Both regimens had similar baseline characteristics. Alternating group had history of shorter intervals pre-switch and extended interval by fewer days with at least a year follow-up.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Table 1: Injection intervals, Visual Acuity, Central Macular Thickness

Table 1: Injection intervals, Visual Acuity, Central Macular Thickness

 

Table 2: Retinal layers fluids changes

Table 2: Retinal layers fluids changes

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×